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Abstract: Background: Iodine deficiency during pregnancy may be associated with lower offspring IQ, but
there are few data on the safety and efficacy of maternal iodine supplementation on child development.
In a previously reported multi-center randomized trial conducted in Thailand and India, we assessed
the effect of iodine supplementation in mildly iodine-deficient pregnant women on offspring development.
In this secondary analysis of that trial, we report data only from the Thai pregnant women in the
study, who were more iodine deficient at entry. Methods: Pregnant women in Bangkok, Thailand, were
randomized to receive daily 200 ฀g oral iodine or placebo until delivery. We assessed thyroid size and
thyroid function during pregnancy and cognitive and motor development at ages 1, 2, and 5.7 years.
The trial was registered at www.clinicaltrials.gov/NCT00791466. Findings: Women (n = 514) entered
the trial between November 2008 and March 2011 at a mean ± SD gestational age of 11 ± 2.8 weeks;
their median (IQR) UIC was 112 (75, 170) ฀g/L. Mean compliance with supplementation was 88%. We
assessed 397 mothers in the 3rd trimester, 231 infants at age 2 y, and 157 children at mean age 5.7 y.
During pregnancy, there was a slightly greater decrease in free and total thyroxine concentrations in the
iodine group (p < 0.05). At age 2 years, the iodine group had borderline lower scores for combined fine
and gross motor function (p = 0.05), but there were no other significant differences in development. At
5.7 years, there were no significant group differences in child development. Conclusion: Daily iodine
supplementation in mildly iodine deficient pregnant women was associated with small negative effects
on maternal thyroxine concentrations, but did not affect child development. The safety and efficacy of
iodine supplementation in mildly-iodine deficient pregnant women needs to be evaluated further in large
randomized controlled trials.
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Background: Iodine deficiency during pregnancymay be associatedwith lower offspring
IQ, but there are few data on the safety and efficacy of maternal iodine supplementation
on child development. In a previously reported multi-center randomized trial conducted
in Thailand and India, we assessed the effect of iodine supplementation in mildly
iodine-deficient pregnant women on offspring development. In this secondary analysis
of that trial, we report data only from the Thai pregnant women in the study, who were
more iodine deficient at entry.
Methods: Pregnant women in Bangkok, Thailand, were randomized to receive daily 200
µg oral iodine or placebo until delivery. We assessed thyroid size and thyroid function
during pregnancy and cognitive and motor development at ages 1, 2, and 5.7 years.
The trial was registered at www.clinicaltrials.gov/NCT00791466.
Findings: Women (n = 514) entered the trial between November 2008 and March
2011 at a mean ± SD gestational age of 11 ± 2.8 weeks; their median (IQR) UIC was
112 (75, 170) µg/L. Mean compliance with supplementation was 88%. We assessed
397 mothers in the 3rd trimester, 231 infants at age 2 y, and 157 children at mean age
5.7 y. During pregnancy, there was a slightly greater decrease in free and total thyroxine
concentrations in the iodine group (p < 0.05). At age 2 years, the iodine group had
borderline lower scores for combined fine and gross motor function (p = 0.05), but
there were no other significant differences in development. At 5.7 years, there were no
significant group differences in child development.
Conclusion: Daily iodine supplementation in mildly iodine deficient pregnant women
was associated with small negative effects on maternal thyroxine concentrations, but
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did not affect child development. The safety and efficacy of iodine supplementation in
mildly-iodine deficient pregnant women needs to be evaluated further in large randomized
controlled trials.
Keywords: iodine deficiency, supplementation, pregnancy, brain development, cognition, infants, children, thyroid
BACKGROUND
Adequate iodine intake is important throughout the life
cycle (1), but is particularly critical during pregnancy, as
iodine is an essential component of thyroid hormones that
are needed for normal fetal development (2, 3). Pregnancy
sharply increases the requirement for iodine, and WHO
recommends an iodine intake of 250 µg/d for pregnant
women, compared to 150 µg/d for non-pregnant women (4).
Thus, pregnant women are particularly vulnerable to iodine
deficiency (ID) when dietary iodine supply is low. The WHO
suggests a median (m) urinary iodine concentration (UIC)
< 150 µg/L in a population of pregnant women indicates
ID (4).
In regions of severe iodine deficiency (a mUIC in
pregnant women of <50 µg/L) and endemic goiter, iodine
supplementation in pregnancy improves maternal thyroid
status and child neurodevelopment (2). However, whether
mild-to-moderate maternal ID (a mUIC of 50–149 µg/L)
increases risk for maternal thyroid disorders or low IQ in the
offspring is unclear (2). A recent systematic review (5) that
examined the effects of iodine supplementation in pregnant
women with mild-to-moderate ID (defined as a baseline mUIC
of 50–149 µg/L) concluded there is little evidence to support
recommendations for iodine supplementation in pregnancy
in areas of mild deficiency (6, 7). Iodine supplementation
may not be without risk: abrupt increases in iodine intake
can impair thyroid function and the fetal thyroid appears
particularly vulnerable to this effect (8). A large cross-sectional
study in Chinese pregnant women reported a mUIC >
250 µg/L increased risk for mild maternal hypothyroidism
(9) and two cohort studies assessing the effect of iodine
supplementation in European pregnant women have reported
supplementation had negative effects on infant psychomotor
development (10–12).
As highlighted by Dineva et al. (5), the best evidence
to date on this issue comes from our previous randomized
controlled trial (RCT) in which pregnant women in India and
Thailand (n = 832) were randomized to receive daily 200 µg
oral iodine or placebo until term (13). Iodine supplementation
had no significant effect on child neurodevelopment measured
at mean age 5.4 years (13). A limitation of this study was
that, although overall the baseline mUIC indicated mild iodine
deficiency, the mUIC at the 2 study sites differed: in Thailand,
the mUIC was 112 µg/L, while in India, the mUIC was
188 µg/L. Thus, many pregnant women enrolled in India
may have been iodine sufficient at baseline. Therefore, in
this secondary analysis, we have included data from only
the Thai cohort, who were more clearly iodine deficient
at baseline.
METHODS
The study was a randomized, placebo-controlled, double-blind
intervention trial; the detailed methods have been described
previously (13). The study site was Ramathibodi Hospital of
Mahidol University in Bangkok, Thailand. At the time of our
intervention, household coverage with adequately iodized salt
was ≈60% in Thailand, and school-aged children were iodine
sufficient based on their median UIC (13). Ethical review boards
at Ramathibodi Hospital and at Wageningen University &
Research, the Netherlands, approved the study in two steps: the
first approval was for studies to 2 years postpartum and the
second follow-on approval to 5–6 years postpartum (13). All
participating women gave written informed consent, and the
study was registered at ClinicalTrials.gov, NCT00791466.
Inclusion criteria were: (1) singleton pregnancy; (2) age 18–
40 years; (3) gestational age ≤14 weeks; (4) not lactating; (5)
generally healthy; (6) no use of iodine containing supplements.
We excluded women with a TSH >6 mIU/L at screening and
referred them for treatment. We randomized women, stratified
by site, to receive 200 µg iodine given as potassium iodide
tablets (Merck, Darmstadt, Germany) or an identical placebo
tablet (Merck, Darmstadt, Germany) taken daily until delivery.
We gave out tablets at monthly visits and assessed compliance
by tablet counting and assessed side effects using a questionnaire
(13). At baseline and during the 2nd (20–24 weeks) and 3rd
(30–33 weeks) trimester, we measured maternal weight and
height, collected venipuncture blood for measurement of thyroid
functions, collected a spot urine sample for measurement of UIC;
and measured thyroid volume by using ultrasound.
When children were 1, 2, and between 5 and 6 years, we
measured height and weight, obtained a spot urine sample and
a fingerprick blood sample which was spotted onto filter paper.
At 1 and 2 years postpartum, we administered the Bayley Scales
of Infant Development (BSID)-III to obtain scores for cognitive,
language and motor development (13). We used raw scores as
age-specific norms were not available for the Thai population.
The BSID-III raw scores were adjusted for infant’s gestational age
at birth. In children at 5–6 years, to assess verbal, performance
and full-scale IQ, we administered the Wechsler Preschool
and Primary Scale of Intelligence (WPPSI)-III (13). To assess
executive functions, we used the Behavior Rating Inventory of
Executive Function (BRIEF)-P (13). Details of the developmental
tests have been previously described (13).
We determined UIC by using spectrophotometry and thyroid
function, thyroglobulin and TPO-Ab were measured using
immunoassays, as previously described (13). With the exception
of TSH and total thyroxine during pregnancy, we used the
manufacturer’s reference ranges. For TSH during pregnancy, we
used trimester specific reference ranges: 0.1–2.5 mIU/L for 1st
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trimester, 0.2–3.0 mIU/L for 2nd trimester, and 0.3–3.0 mIU/L
for 3rd trimester (14). For total thyroxine until week 6, we
used the reference range of 58–161 nmol/L; from week 7, we
increased the upper reference range by 5% per week until week
15; fromweek 16 until delivery, wemultiplied the non-pregnancy
reference range by 1.5 and used the resulting range of 87–241.5
nmol/L as a reference (15).
In children, TSH and total thyroxine concentrations were
measured on filter paper by fluoroimmunoassay (TSH, DELFIA
NeoTSH, PerkinElmer Life Sciences, Turku, Finland; and T4,
Delfia Neonatal T4 kit, PerkinElmer Life Sciences). We applied
age-specific reference ranges for TSH and total thyroxine as
supplied by the manufacturer: TSH 0.1–3.7 mIU/L and total
thyroxine 65–165 nmol/L.
Data and Statistical Analysis
As described previously (13), to discriminate a 5-point difference
on the full scale IQ score of the WPPSI-III between groups
at 5 and 6 years, with a standard deviation of 15, α of 0.05
(two-sided), and 80% power, we estimated we would need
142 children in each group. We used WHO criteria based
on the mUIC to classify adequate iodine intake for pregnant
women (≥150 µg/L) infants and children (≥100 µg/L) (4).
Overt hypothyroidism was defined as a high TSH and a low
total thyroxine; subclinical hypothyroidism as a high TSH and
a normal total thyroxine; isolated hypothyroxinemia (in the
pregnant women) was defined as a normal TSH and a low
total thyroxine; overt hyperthyroidism was defined as a low
TSH and a high total thyroxine; subclinical hyperthyroidism
as a low TSH and a normal total thyroxine. From the thyroid
ultrasound measurements, we calculated thyroid volume as
previously described (4).
We conducted data analysis with the R statistical
programming environment (version 3.6.1) (16) using packages
nlme and lme4, as previously described (13). Data were presented
as mean (±SD) for normally distributed data, median (IQR)
for non-normal data, and percentage (n) for prevalence. We
assessed the intervention effect by fitting linear mixed effects
models to continuous dependent variables and by fitting logistic
regression mixed effects models to categorical dependent
variables, as described previously (13). During gestation, the
fixed effects were defined as treatment, trimester, treatment
by trimester, maternal education, household average monthly
income, maternal age and maternal BMI at trial entry to improve
the model fit. For the primary outcomes in children at 5–6 years
and the BDIS-III at 1 and 2 year, we defined the fixed effects
as treatment, household average monthly income, maternal
education, child’s birthweight, child’s age and child’s sex. We
defined subject as the random effect. We ran a sensitivity analysis
for maternal outcomes during pregnancy. The pregnant women
in the iodine group were divided into three tertiles based on their
mean UIC from the three trimesters. We assessed the effect of
the sensitivity analysis by fitting linear mixed effect models and
by fitting logistic regression mixed effect models, as previously
described, with two additional fixed effects defined as tertile and
tertile by time. Statistical significance was set at P < 0.05.
RESULTS
We recruited subjects between November 2008 and March 2011,
and completed the data collection in July 2016. We assessed
709 participants for eligibility; 195 declined to participate or did
not meet the inclusion criteria (Figure 1). 514 pregnant women
were enrolled and randomized to the two groups. Participants’
baseline characteristics are shown in Table 1. In the iodine and
placebo groups, mean (±SD) gestational age at trial entry was
10.9 (2.8) and 11.0 (2.9) weeks and mUIC (IQR) was 112 (76–
163) and 110 (70–172) µg/L, indicating mild iodine deficiency
(4). There were no significant differences between the groups
in any of the baseline variables, with the exception of a slightly
higher free thyroxine in the iodine group (p = 0.04) (Table 1).
The prevalence of mild thyroid hypofunction, that is, isolated
hypothyroxinemia and/or subclinical hypothyroidism, was about
12% in both groups.
Mean compliance with supplementation was 88%. Table 2
shows the maternal variables during pregnancy, by group. We
analyzed data from 412 women in the 2nd trimester and 394
women in the 3rd trimester. In the 2nd and 3rd trimesters,
mUIC in the iodine group was 224 and 233µg/L, indicating clear
iodine sufficiency in the iodine group (4), while in the placebo
group, it was 144 and 155 µg/L, suggesting borderline iodine
sufficiency (p < 0.001). During pregnancy, maternal free and
total thyroxine concentrations were lower in the iodine group as
compared to placebo (p = 0.0003, and p = 0.02, respectively).
In a sensitivity analysis based on UIC tertiles during pregnancy
restricted to the iodine group, we saw a steeper decline in free
and total thyroxine concentrations in women over increasing
tertiles of UIC, but these trends were not statistically significant.
As expected, maternal thyroglobulin concentrations were lower
in the iodine group (p = 0.0006). There were no significant
group differences in any thyroid disorders (Table 2). The analysis
were conducted with and without gestational age as fixed factor,
but the results did not change for any of the parameters (data
not shown).
We analyzed data from 193 infants at 1 year, 231 infants
at age 2 y and 157 children at mean age 5.7 y; attrition was
balanced between groups and the main reason was a move
away from the trial area around delivery (Figure 1). At age 2
years, the TSH concentrations were lower in the iodine group
(p = 0.03). We did not observe significant group differences in
anthropometrics, UIC and total thyroxine in infants at age 1, 2,
and 5.7 years (Table 3). At age 1 year, there were no significant
group differences on the BSID-III (Table 4). At age 2 years, the
iodine group had lower scores for gross motor (p = 0.07) and
combined fine and gross motor function (p = 0.05) with mean
differences [95% CI] of −0.8 [−1.6 to 0.03] and −1.1 [−2.2 to
0.03], respectively (Table 4). This finding was in part driven by
the low motor scores of two children; after removing these two
cases from the analysis, the differences in the gross motor and
combined motor function scores were reduced (mean diff=-0.6,
p= 0.14 and mean diff=-0.8, p= 0.12, respectively). At 5.7 years,
there were no significant group differences on the WPPSI-III or
the BRIEF-P (Table 5). However, on all four measured categories
of the WPPSI-III, verbal IQ, performance IQ, processing speed
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FIGURE 1 | Study overview.
and full scale IQ, the iodine group had lower scores with mean
differences between 0.2 and 2.0 points, although these differences
were not statistically significant. As discussed below, a limitation
of this secondary analysis is that the sample size at 5.7 years (n=
157) was below the estimated sample size needed to discriminate
a 5-point difference on theWPPSI (13). All adverse events during
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TABLE 1 | Baseline characteristics of the Thai pregnant women, by group.
Iodine Placebo
n Value n Value
Agea, y 251 30.0 (5.2) 263 29.7 (5.1)
BMI, kg/m2 250 21.5 (19.5–23.6) 263 21.5 (19.6–23.8)
Gestational age, wk 251 10.9 (2.8) 263 11.0 (2.9)
First pregnancy, n (%) 251 118 (47) 263 106 (40)
Using iodized salt at home, n (%) 251 222 (88) 263 231 (88)
Urinary iodine concentrationb, µg/L 248 112 (76–163) 260 110 (70–172)
Thyroid volume, mL 251 8.58 (1.88) 263 8.72 (2.08)
Thyroid stimulating hormone, mIU/L 245 1.0 (0.6–1.7) 258 1.1 (0.7–1.7)
Thyroglobulin, µg/L 232 9.38 (4.65–16.53) 239 9.57 (6.36–16.85)
Free T3, ng/L 237 3.13 (2.70–3.58) 252 3.21 (2.78–3.68)
Total T3, nmol/L 248 1.85 (1.56–2.15) 262 1.85 (1.54–2.19)
Free T4, ng/L 240 1.08 (0.98–1.20) 258 1.07 (0.95–1.18)
Total T4, nmol/L 247 118 (101–138) 259 117 (102–135)
TPO-Ab, IU/mL 251 17.7 (11.6–24.7) 263 16.2 (11.1–26.1)
Raised TPO-Ab >35 IU/mL, n (%) 251 37 (15) 263 40 (15)
Isolated hypothyroxinaemia, n (%) 243 4 (2) 256 2 (1)
Subclinical hypothyroidism, n (%) 243 24 (10) 256 26 (10)
Overt hypothyroidism, n (%) 243 0 (0) 256 0 (0)
Subclinical hyperthyroidism, n (%) 243 10 (4) 256 11 (4)
Overt hyperthyroidism, n (%) 243 3 (1) 256 1 (<1)
aContinuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables and frequencies were analyzed using mixed effect logistic
regression testing the differences between treatment populations (iodine or placebo).
bMean (±SD) (all such values).
T3, tri-iodothyronine; T4, thyroxine; TPO-Ab, antithyroid peroxidase antibodies.
gestation and delivery were recorded; there was no significant
group difference in frequency of adverse events: 14 women
in the iodine group and 16 in the placebo group experienced
adverse events.
DISCUSSION
This secondary analysis of our previous RCT provides new
insights into the effects of iodine supplementation in mildly
iodine deficient women. The Thai pregnant women included in
this secondary analysis at baseline had a mUIC of 112 µg/L; this
degree of mild maternal iodine deficiency is common worldwide:
in national studies of pregnant women in Europe, ≈2/3rds
reported mild iodine deficiency based on the mUIC (17). The
200 µg dose of iodine given in this study was effective: in the
iodine group, mUIC increased to 224–233 µg/L in the 2nd and
3rd trimesters, at the upper end of mUIC reference range for
pregnancy of 150–249 µg/L (4). However, the mUIC in the
placebo group also increased to a lesser degree (Table 2); this
may have been due to a physiological increase in renal iodine
clearance (2) and/or to increased awareness of iodine nutrition
and consumption of more iodine-rich foods.
Iodine supplementation was associated with a small but
significant negative effect on maternal thyroxine concentrations.
Although there was no significant effect on TSH concentrations,
free and total thyroxine concentrations declined slightly but
significantly more in the iodine group over the duration of
pregnancy, as reported before with a different statistical approach
(18). The small observed differences in maternal thyroxine
concentrations may not be of clinical significance, as there were
no significant group differences in maternal hypothyroidism
or isolated hypothyroxinemia between groups (Table 2). In
seven previous RCTs of maternal iodine supplementation
looking at maternal thyroid function (19–26), there were no
significant differences in maternal TSH between the iodine
and control groups. Six found no significant difference in
maternal free (19, 21–24) or total thyroxine concentration
(25) between the iodine and control groups, while one found
a slightly higher total thyroxine concentration (26) in the
iodine group. Another recent intervention study comparing
daily administration of a multiple micronutrient supplement
containing 300 µg or an iron and folic acid supplement in
moderately iodine deficient women (mUIC 51 µg/L (IQR 33–
82) found no differences in maternal TSH or total thyroxine
concentration (27). Other intervention studies (that were not
RCTs) found no difference in free thyroxine concentrations
comparing different doses of iodine supplements (28, 29), but
one reported a lower free thyroxine concentration in women
receiving iodine supplements (30). One study reported that
women who started taking 150 µg iodine/day (as part of
a multivitamin/mineral tablet) had a significantly lower free
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TABLE 2 | Maternal outcomes in Thai pregnant women, by group.
Baseline Second trimester Third trimester
n Value n Value n Value Pa
Urinary iodine concentrationb, µg/L
Iodine 248 112 (76–163) 167 224 (133–345) 171 233 (140–313) <0.001
Placebo 260 110 (70–172) 152 144 (86–237) 185 155 (108–211)
Thyroid volumec, mL
Iodine 251 8.58 (1.88) 185 8.44 (1.92) 176 8.17 (2.05) 0.59
Placebo 263 8.72 (2.08) 171 8.54 (2.25) 190 8.20 (1.93)
Thyroid stimulating hormone, mIU/L
Iodine 245 1.0 (0.6–1.7) 173 1.2 (0.8–1.8) 156 1.1 (0.7–1.7) 0.13
Placebo 258 1.1 (0.7–1.7) 165 1.2 (0.8–1.7) 177 1.3 (0.8–1.8)
Thyroglobulin, µg/L
Iodine 232 9.38 (4.65–16.53) 167 8.60 (4.65–15.45) 151 9.78 (5.50–18.10) <0.001
Placebo 239 9.57 (6.36–16.85) 151 10.4 (5.65–15.80) 175 11.9 (6.48–22.25)
Free tri-iodothyronine, ng/mL
Iodine 237 3.13 (2.70–3.58) 162 3.35 (2.82–3.99) 150 3.32 (2.96–3.83) 0.57
Placebo 252 3.21 (2.78–3.68) 149 3.22 (2.89–3.72) 175 3.38 (2.91–3.85)
Total tri-iodothyronine, nmol/L
Iodine 248 1.85 (1.56–2.15) 180 2.38 (2.03–2.77) 164 2.44 (2.13–2.73) 0.45
Placebo 262 1.85 (1.54–2.19) 163 2.34 (2.00–2.68) 182 2.42 (2.13–2.86)
Free thyroxine, ng/dL
Iodine 240 1.08 (0.98–1.20) 175 0.78 (0.72–0.88) 161 0.77 (0.68–0.84) <0.001
Placebo 258 1.07 (0.95–1.18) 162 0.81 (0.75–0.88) 185 0.79 (0.71–0.87)
Total thyroxine, nmol/L
Iodine 247 118 (101–138) 175 114 (102–129) 161 113 (100–129) 0.02
Placebo 259 117 (102–135) 167 116 (102–131) 182 117 (101–131)
TPO-Ab, IU/mL
Iodine 251 17.7 (11.6–24.7) 183 13.7 (8.5–21.6) 170 12.8 (5.5–19.6) 0.69
Placebo 263 16.2 (11.1–26.1) 171 14.2 (9.0–21.7) 192 11.7 (6.2–18.9)
Raised TPO-Ab >35 IU/mL, n (%)
Iodine 251 37 (15) 183 21 (11) 170 11 (6) 0.89
Placebo 263 40 (15) 171 15 (9) 192 13 (7)
Isolated hypothyroxinaemia, n (%)
Iodine 243 4 (2) 170 19 (11) 155 13 (8) 0.98
Placebo 256 2 (1) 164 11 (7) 176 14 (8)
Subclinical hypothyroidism, n (%)
Iodine 243 24 (10) 170 11 (6) 155 6 (4) 0.57
Placebo 256 26 (10) 164 6 (4) 176 4 (2)
Overt hypothyroidism, n (%)
Iodine 243 0 (0) 170 2 (1) 155 1 (1) 0.16
Placebo 256 0 (0) 164 0 (0) 176 0 (0)
Subclinical hyperthyroidism, n (%)
Iodine 243 10 (4) 170 4 (2) 155 7 (5) 0.51
Placebo 256 11 (4) 164 4 (2) 176 4 (2)
Overt hyperthyroidism, n (%)
Iodine 243 3 (1) 170 0 (0) 155 0 (0) 0.25
Placebo 256 1 (<1) 164 0 (0) 176 0 (0)
Sum of thyroid disordersd, n(%)
Iodine 251 41 (16) 183 36 (20) 170 27 (16) 0.78
Placebo 263 40 (15) 171 21 (12) 192 22 (11)
aContinuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables. Frequencies were analyzed using mixed effect logistic
regression. The interaction effect of treatment by time was tested while controlling for household average monthly income, maternal education, maternal age and maternal BMI at
trial entry.
bMedian (IQR) (all such values).
cMean (±SD) (all such values).
dSum of the following disorders: isolated hypothyroxinaemia, subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism.
TPO-Ab, antithyroid peroxidase antibodies.
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TABLE 3 | Secondary outcomes in Thai children, at age 1, 2, and 5.7 years, by group.
1 year 2 year 5.7 year
n Value Pa n Value Pa n Value Pa
Sex, male, n (%)
Iodine 92 38 (41) 0.43 115 50 (43) 0.56 77 32 (42) 0.84
Placebo 104 49 (47) 118 55 (47) 80 35 (44)
Ageb, years
Iodine 92 1.0 (0.1) 0.20 114 2.1 (0.2) 0.97 77 5.6 (0.6) 0.36
Placebo 101 1.0 (0.1) 117 2.1 (0.2) 80 5.7 (0.6)
Bodyweight, kg
Iodine 92 9.3 (1.2) 0.94 113 12.3 (2.0) 0.98 77 19.7 (4.6) 0.08
Placebo 101 9.3 (1.2) 116 12.3 (2.0) 80 21.0 (6.2)
Height, cm
Iodine 92 75.0 (3.5) 0.21 114 87.0 (3.6) 0.74 77 112.1 (6.0) 0.32
Placebo 101 74.6 (3.0) 117 86.9 (4.0) 80 113.2 (6.4)
Height-for-age Z score
Iodine 91 −0.1 (1.3) 0.20 114 −0.2 (1.1) 0.69 77 −0.2 (1.0) 0.34
Placebo 100 −0.3 (1.1) 117 −0.3 (1.1) 80 −0.1 (1.0)
Stunting, n (%)
Iodine 91 5 (5) 0.53 114 6 (5) 0.77 77 2 (3) 0.17
Placebo 100 4 (4) 117 7 (6) 80 0 (0)
Urinary iodine concentrationc, µg/L
Iodine 58 239 (136–386) 0.29 82 231 (149–293) 0.62 77 243 (154–350) 0.70
Placebo 64 273 (184–438) 86 223 (160–325) 78 260 (180–311)
Total thyroxine, nmol/L
Iodine 75 58.5 (41.6–80.9) 0.39 103 64.0 (49.3–83.3) 0.42 76 80.0 (70.1–91.0) 0.11
Placebo 86 60.8 (45.4–88.3) 107 62.6 (47.7–79.8) 77 83.3 (69.1–99.7)
Thyroid stimulating hormone, mIU/L
Iodine 75 0.7 (0.6–1.0) 0.11 103 0.8 (0.6–1.0) 0.03 76 0.9 (0.7–1.1) 0.12
Placebo 86 0.8 (0.6–1.0) 107 0.9 (0.6–1.1) 77 0.9 (0.7–1.2)
aContinuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables. Frequencies were analyzed using mixed effect logistic
regression. The interaction effect of treatment by time was tested while controlling for household average monthly income, maternal education, child’s birthweight, child’s age and
child’s sex.
bMean (±SD) (all such values).
cMedian (IQR) (all such values).
thyroxine concentrations during pregnancy than women who
started using iodized salt before pregnancy (31). Most cross-
sectional studies associating iodine supplements with maternal
thyroxine concentrations found no difference in free thyroxine
(32–34) or total thyroxine concentrations (35), although two
studies reported lower free thyroxine (36, 37) in iodine-
supplement users. A large cross-sectional Chinese study (in an
iodine-sufficient region) reported higher mUICs during early
pregnancy were associated with mild maternal hypothyroidism
(9): among pregnant women (n= 7,190) at 4–8 wk gestation, spot
UICs of 250–499µg/L and≥ 500µg/L were associated with a 1.7-
fold and a 2.2-fold increased risk of subclinical hypothyroidism,
respectively, and the latter UIC with a 2.9-fold increased risk
of isolated hypothyroxinemia (9). Our study suggests that
during mild maternal iodine deficiency, thyroid adaptation
maintains maternal thyroxine concentrations within the normal
range, and although there may be a small risk of decreased
thyroxine concentrations during iodine supplementation, the
data remain uncertain.
Notably, we found borderline non-significant group
differences in child motor outcomes at age 2 years (Table 4).
In the Spanish Infancia y Medio Ambiente–Environment
and Childhood (INMA) Study cohort, in Valencia (n = 691),
maternal supplemental iodine intake of ≥150 µg/day, compared
with <100 µg/day, was associated with a significant 5.2-point
decrease in psychomotor scores and a 1.8-fold increase in the
odds of a psychomotor score <85 at age 1 year (10). When
pooled with the three other sites in INMA (n = 1,519), the
overall increase in risk for a psychomotor score < 85 associated
with maternal supplemental iodine intake of ≥150 µg/day
remained significant (OR = 1.7, 95% CI: 1.1, 2.6) (11). When
stratified by maternal iodized salt consumption, this increase
in risk was greater for women who consumed iodized salt,
suggesting that the extra dose of iodine from supplements might
result in iodine excess (11). However, these negative effects on
child development in the INMA cohort were not confirmed at
age 4–5 years (38). Similarly, we found no significant differences
in cognitive outcomes at age 5.7 years, but on all four measured
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TABLE 4 | Cognitive outcomes in Thai children, at age 1 and, 2 years, by group.
n 1 year Mean difference (95% CI) P n 2 year Mean difference (95% CI) Pa
BSID-III, Cognitiveb
Iodine 85 42 (40–45) 1.1 (0.01 to 2.3) 0.08 108 62 (59–64) −0.2 (−1.4 to 0.9) 0.52
Placebo 92 42 (40–43) 110 62 (59–65)
BSID-III, Language receptive
Iodine 85 12 (11–13) 0.4 (−0.04 to 0.8) 0.18 107 26 (24–29) 0.5 (−0.7 to 1.7) 0.60
Placebo 90 12 (11–12) 108 25 (23–28)
BSID-III, Language expressive
Iodine 85 13 (11–14) −0.05 (−0.8 to 0.7) 0.65 104 29 (26–31) 0.9 (−0.4 to 2.3) 0.38
Placebo 90 13 (12–15) 104 29 (26–31)
BSID-III, Language combined
Iodine 85 25 (23–28) 0.3 (−0.6 to 1.3) 0.79 104 55 (50–59) 1.5 (−0.8 to 3.8) 0.40
Placebo 90 25 (23–27) 104 54 (49–58)
BSID-III, Fine motor
Iodine 85 29 (28–30) 0.3 (−0.3 to 0.9) 0.41 106 37 (36–39) −0.3 (−0.9 to 0.4) 0.37
Placebo 90 29 (27–30) 108 38 (36–39)
BSID-III, Gross motor
Iodine 84 41 (38–44) −0.2 (−1.5 to 1.0) 0.39 104 54 (52–55) −0.8 (−1.6 to 0.03) 0.07
Placebo 90 41 (38–44) 107 54 (52–56)
BSID-III, Motor combined
Iodine 84 70 (66–73) 0.1 (−1.4 to 1.6) 0.76 103 91 (89–93) −1.1 (−2.2 to 0.03) 0.05
Placebo 90 70 (67–73) 107 92 (90–94)
aData were analyzed using linear mixed effect models testing treatment effect while controlling for household average monthly income, maternal education, child’s birthweight, child’s
age and child’s sex.
bMedian (IQR) all such values.
BSID-III, Bayley Scales of Infant Development Third Edition.
categories of the WPPSI-III, the iodine group had lower scores,
with mean differences between 0.2 and 2.0 points (Table 5).
In an observational study from Norway (n = 851, mUIC=78
µg/L), maternal use of iodine-containing supplements (150–200
µg/d) during pregnancy predicted poorer fine motor skills
(standardized beta = −0.10, p = 0.15) and gross motor skills
(standardized beta = −0.18, p = 0.02), measured using the
BSID-III at 18 months (12).
Iodine readily crosses the placenta and excessive iodine intake
during pregnancy can cause iodine-induced hypothyroidism in
the fetus and newborn (39). This phenomenon is known as the
acute Wolff-Chaikoff effect and in adults, an “escape” from the
acute Wolff-Chaikoff effect usually occurs after a few days of
exposure. However, the immature fetal thyroid gland is unable
to escape from the acute Wolff-Chaikoff effect, making the
fetus and newborn vulnerable to iodine-induced hypothyroidism
(39–41). Fetal hypothyroidism may develop in the setting of
a large iodine load even if maternal thyroid function remains
normal (39). Although most reports of fetal and newborn
iodine-induced hypothyroidism have occurred after very large
maternal doses of iodine (typically in the mg range of intake),
it is possible that lower supplemental doses could cause this
effect in susceptible pregnancies. Therefore, iodine intake during
pregnancy should be high enough to ensure normal thyroid
function in the mother and fetus, but more iodine is not
necessarily better.
This secondary analysis has several limitations. The women
began iodine supplementation at mean gestational age of 11 wk.
It is possible that beginning supplementation earlier would have
resulted in different findings, as the fetal brain rapidly develops
in the 1st trimester (2, 3). However, we did not find an effect of
gestational age at entry on any of the developmental outcomes
in secondary analysis of the iodine group. We used the mUIC
from spot samples to classify population iodine status in pregnant
women per recommendations from WHO, but UIC is a poor
marker of individual status (4). Thus, it is uncertain whether all
women included in this study were iodine deficient and exposure
misclassification may have biased our results. The dropout rate
was high around delivery but attrition was balanced between
groups. The final sample size at 5.7 years (n = 157) was below
the estimated sample size (n = 284) needed to discriminate a 5-
point difference on the WPPSI between groups; thus, the lack
of a group effect on cognitive outcomes at age 5.7 years in this
secondary outcome is inconclusive.
In conclusion, in this secondary analysis, daily iodine
supplementation with 200 µg iodine in mildly iodine deficient
pregnant women did not benefit their thyroid function or
improve child development. Iodine supplementation resulted
in small but significant negative effects on maternal thyroid
function, but did not affect child development. Currently, the
American and European Thyroid Associations (6, 7) recommend
women take a supplement containing 150 µg iodine daily
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TABLE 5 | Cognitive outcomes in Thai children, at mean age 5.7 years, by group.
n 5.7 years Mean difference (95% CI) Pa
WPPSI-III, verbal IQb
Iodine 77 90.9 (± 9.3) −0.5 (−3.5 to 2.6) 0.78
Placebo 79 91.3 (± 10.2)
WPPSI-III, performance IQ
Iodine 77 101.7 (± 12.9) −2.0 (−6.2 to 2.3) 0.42
Placebo 79 103.7 (± 14.3)
WPPSI-III, processing speed
Iodine 77 114.3 (± 12.4) −0.2 (−4.2 to 3.8) 0.75
Placebo 79 114.5 (± 13.0)
WPPSI-III, full scale IQ
Iodine 77 97.5 (± 10.4) −1.0 (−4.4 to 2.3) 0.55
Placebo 79 98.5 (± 11.1)
BRIEF-P, global executive
Iodine 77 112.8 (± 19.1) 0 (−6.0 to 6.0) 0.98
Placebo 79 112.7 (± 19.2)
aData were analyzed using linear mixed effect models testing treatment effect
while controlling for household average monthly income, maternal education, child’s
birthweight, child’s age and child’s sex.
bMean (±SD) (all such values).
BRIEF-P, Behavior Rating Inventory of Executive Function Preschool Version; IQ,
intelligence quotient; WPPSI-III, Wechsler Preschool and Primary Scale of Intelligence
Third Edition.
during pregnancy. In contrast, WHO does not recommend
maternal iodine supplements in countries with iodized salt
programs (42), concluding that if women are iodine-replete
before they enter pregnancy, they can cover their requirements
by increasing fractional clearance of plasma iodide and drawing
from thyroidal iodine stores. Our findings suggest current
expert recommendations for iodine supplementation in this
setting need to be evaluated in large randomized controlled
trials that assess both safety and efficacy. Also, it would be
valuable for future intervention trials to include pregnant
women with moderate iodine deficiency (e.g., with a mUIC
<100 µg/L).
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